Trump To Implement Automotive Tariffs On April 2
U.S. President Donald Trump has said he plans to implement tariffs on imported motor vehicles and auto parts starting April 2, dealing a potential blow to Canada’s manufacturing sector. Trump’s comment on auto tariffs contained few other details, and did not say whether the new duties will apply to all automotive imports. However, economists and industry analysts continue to warn that tariffs on U.S. imports effectively raise prices for American consumers. The American Automotive Policy Council, which represents General Motors (GM), Ford Motor Co. (F), and Stellantis (STLA), has said the proposed auto tariffs could add an additional $6,000 U.S. to the cost of a new vehicle sold in America. Analysts have warned that any tariffs will damage the U.S. automotive manufacturing industry that is closely intertwined with Canada and Mexico.About half of all the vehicles sold in the U.S. are manufactured within the country. The other 50% are imported from Mexico and Canada, as well as Japan and Germany.The three major U.S.-based automotive manufacturers, GM, Ford and Stellantis have raised concerns about potential tariffs.Ford CEO Jim Farley has said that Trump’s proposed tariffs on Mexico and Canada will “blow a hole” in the North American auto industry.The stocks of both General Motors and Ford are down so far this year as investors try and assess the impacts of any tariffs levied on vehicles and auto parts.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


